The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Top Cited Papers
- 12 February 2019
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 19 (3), 133-150
- https://doi.org/10.1038/s41568-019-0116-x
Abstract
Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4 (CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success in the treatment of different cancer types. Yet, only a subset of patients derive clinical benefit. It is thus critical to understand the determinants driving response, resistance and adverse effects. In this Review, we discuss recent work demonstrating that immune checkpoint inhibitor efficacy is affected by a combination of factors involving tumour genomics, host germline genetics, PD1 ligand 1 (PDL1) levels and other features of the tumour microenvironment, as well as the gut microbiome. We focus on recently identified molecular and cellular determinants of response. A better understanding of how these variables cooperate to affect tumour–host interactions is needed to optimize the implementation of precision immunotherapy.Keywords
This publication has 253 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumorsJCI Insight, 2012
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic MelanomaClinical Cancer Research, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockadeProceedings of the National Academy of Sciences of the United States of America, 2008
- HLA class I supertypes: a revised and updated classificationBMC Immunology, 2008
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research, 2007
- A TGFβRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8 + T cellsCancer Immunology, Immunotherapy, 2001